SPOTLIGHT -
Epigenetic Variations in Prostate Tumors May Determine Choice Between Definitive Treatment and Active Surveillance
Prostate cancer is the most common cancer and second leading cause of cancer mortality in American men. Nevertheless, it is estimated that only 3% of the patients will die because of their cancer, while the majority will die of competing causes.
Read More
Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC
Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases
Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC
Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC
